267 related articles for article (PubMed ID: 17635237)
1. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.
Lim ST; Fei G; Quek R; Lim LC; Lee LH; Yap SP; Loong S; Tao M
Eur J Haematol; 2007 Aug; 79(2):132-7. PubMed ID: 17635237
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.
Park SC; Jeong SH; Kim J; Han CJ; Kim YC; Choi KS; Cho JH; Lee M; Jung HH; Ki SS; Chang YH; Lee SS; Park YH; Lee KH
J Med Virol; 2008 Jun; 80(6):960-6. PubMed ID: 18428141
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
[TBL] [Abstract][Full Text] [Related]
7. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
[TBL] [Abstract][Full Text] [Related]
8. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers.
Wang F; Xu RH; Han B; Shi YX; Luo HY; Jiang WQ; Lin TY; Huang HQ; Xia ZJ; Guan ZZ
Cancer; 2007 Apr; 109(7):1360-4. PubMed ID: 17326056
[TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy.
Kim YM; Jeong SH; Kim JW; Lee SH; Hwang JH; Park YS; Kim N; Lee JS; Kim HY; Lee DH
J Clin Virol; 2011 Aug; 51(4):241-5. PubMed ID: 21628103
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
11. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
12. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
13. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma.
Chen MH; Hsiao LT; Chiou TJ; Liu JH; Gau JP; Teng HW; Wang WS; Chao TC; Yen CC; Chen PM
Ann Hematol; 2008 Jun; 87(6):475-80. PubMed ID: 18327583
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.
Stroffolini T; Andriani A; Bibas M; Barlattani A
Ann Hematol; 2002 Jan; 81(1):48-9. PubMed ID: 11807636
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
[TBL] [Abstract][Full Text] [Related]
17. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
Nakagawa M; Simizu Y; Suemura M; Sato B
Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease.
Yuan XG; Chen FF; Zhu YM; Hu W; Zhao XY; Jin J
Ann Hematol; 2012 Jun; 91(6):857-61. PubMed ID: 22186829
[TBL] [Abstract][Full Text] [Related]
20. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
Lee GW; Ryu MH; Lee JL; Oh S; Kim E; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Kim WK; Lee JS; Kang YK
J Korean Med Sci; 2003 Dec; 18(6):849-54. PubMed ID: 14676442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
